Azithromycin
- Generic Name
- Azithromycin
- Brand Names
- Azasite, Zithromax, Zmax
- Drug Type
- Small Molecule
- Chemical Formula
- C38H72N2O12
- CAS Number
- 83905-01-5
- Unique Ingredient Identifier
- J2KLZ20U1M
- Background
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...
- Indication
Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis
- Associated Therapies
- -
Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002328
- Locations
- 🇺🇸
Pfizer Central Research, Groton, Connecticut, United States
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Anderson Clinical Research
- Registration Number
- NCT00002192
- Locations
- 🇺🇸
Hampton Roads Med Specialists, Hampton, Virginia, United States
Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002082
- Locations
- 🇺🇸
Univ of Tennessee, Memphis, Tennessee, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Infectious Disease Med Group, Oakland, California, United States
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 720
- Registration Number
- NCT00002122
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCSD Treatment Ctr / Dept of Medicine and Pediatrics, San Diego, California, United States
🇺🇸Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-10-31
- Target Recruit Count
- 91
- Registration Number
- NCT00001023
- Locations
- 🇺🇸
Univ of Maryland at Baltimore / Veterans Adm, Baltimore, Maryland, United States
🇺🇸Denver Public Health Dept, Denver, Colorado, United States
🇺🇸Med College of Virginia / School of Pharmacy, Richmond, Virginia, United States
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-10-25
- Target Recruit Count
- 636
- Registration Number
- NCT00000883
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 90
- Registration Number
- NCT00000641
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 690
- Registration Number
- NCT00000811
- Locations
- 🇺🇸
Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States
🇵🇷San Juan City Hosp, San Juan, Puerto Rico
🇺🇸Texas Children's Hosp / Baylor Univ, Houston, Texas, United States
Treatment of Chronic Cryptosporidiosis in AIDS Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 16
- Registration Number
- NCT00001128
- Locations
- 🇺🇸
Pablo C. Okhuysen, Houston, Texas, United States
A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00000966
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.